CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF) Dilated cardiomyopathy: so many cardiomyopathies! Lateral Wall Dysfunction Signals Onset of Progressive Heart Failure in Left Bundle Branch Block Exercise Intolerance in Patients With Heart Failure: JACC State-of-the-Art Review Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate Metformin Lowers Body Weight But Fails to Increase Insulin Sensitivity in Chronic Heart Failure Patients without Diabetes: a Randomized, Double-Blind, Placebo-Controlled Study Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes The Role of the Pericardium in Heart Failure: Implications for Pathophysiology and Treatment A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation Heart Failure With Recovered Left Ventricular Ejection Fraction: JACC Scientific Expert Panel

Original Research2019 May;21(5):665-675.

JOURNAL:Eur J Heart Fail. Article Link

A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)

McMurray JJV, DeMets DL, DAPA-HF Committees and Investigators. Keywords: protocol; heart failure; sodium-glucose co-transporter 2 inhibitor; type 2 diabetes mellitus

FULL TEXT PDF